Nasopharyngeal Carcinoma - Market Insight, Epidemiology, and Market Forecast - 2034

Key Highlights

• The incidence of nasopharyngeal carcinoma is generally less than 1 per 100,000 individuals. Men are affected about three times more than women by nasopharyngeal carcinoma.
• The available treatments for nasopharyngeal carcinoma include radiation therapy, chemotherapy, and chemoradiation. LOQTORZI (toripalimab) was the first drug approved by the FDA for the treatment of nasopharyngeal carcinoma.
• In April 2025, the US FDA approved ANNIKO (Akeso Biopharma) with cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma.
• In May 2025, BeOne Medicines announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended the approval of TEVIMBRA (tislelizumab) in combination with gemcitabine and cisplatin for the first-line treatment of adult patients with recurrent or metastatic nasopharyngeal carcinoma that is not amenable to curative surgery or radiotherapy. The company anticipates the approval in Europe in the second half of 2025.
• The pipeline is not very robust. However, there are some emerging drugs such as IAE0972 (SunHo Biopharmaceutical), GEN1160 (Genmab), KFA115 ± pembrolizumab (Novartis), and others.
• In the coming years, the nasopharyngeal carcinoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

DelveInsight's “Nasopharyngeal Carcinoma – Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth analysis of nasopharyngeal carcinoma epidemiology, market, and clinical development in nasopharyngeal carcinoma. In addition to this, the report provides historical and forecasted epidemiology and market data as well as a detailed analysis of the nasopharyngeal carcinoma market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Nasopharyngeal carcinoma market report provides real-world prescription pattern analysis, emerging drugs assessment, market share, and uptake/adoption pattern of individual therapies, as well as historical and forecasted nasopharyngeal carcinoma market size from 2020 to 2034 in 7MM. The report also covers current nasopharyngeal carcinoma treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Nasopharyngeal Carcinoma Understanding and Treatment Algorithm

Nasopharyngeal Carcinoma Cancer Overview

Nasopharyngeal carcinoma is a type of head and neck cancer that affects the part of the throat connecting the back of the nose to the back of the mouth (nasopharynx). It is an undifferentiated form of squamous cell carcinoma arising from the epithelium of the nasopharynx. There are mainly three types of nasopharyngeal carcinoma. They all start from epithelial cells that line the nasopharynx. These three types include non-keratinizing undifferentiated carcinoma, non-keratinizing differentiated carcinoma, and keratinizing squamous cell carcinoma. Symptoms of nasopharyngeal carcinoma include a lump in the neck, hearing loss, tinnitus, a blocked or stuffy nose, nosebleeds, headaches, double vision, numbness in the bottom part of your face, swallowing problems, weight loss, and others.

Nasopharyngeal Carcinoma Diagnosis

To diagnose nasopharyngeal carcinoma, a nasopharyngoscopy may be performed to assist doctors in evaluating for nasopharyngeal carcinoma. Other tests include physical examination of the nose, face, and neck and history, x-rays of the head and neck, MRI, CT scan, PET scan, and biopsies (surgical biopsy, core needle biopsy, and excisional biopsy).

Further details related to country-based variations in diagnosis are provided in the report

Nasopharyngeal Carcinoma Treatment

Treatment of nasopharyngeal carcinoma largely depends on the stage of the disease at diagnosis. For early-stage cases (Stage 0 and I), radiation therapy alone is typically sufficient, as these tumors are highly sensitive to radiation. In Stage II, the standard approach is concurrent chemoradiation, most commonly using cisplatin as the chemotherapy agent. This may be followed by additional chemotherapy to reduce the risk of recurrence. For Stage III and IVA disease, treatment options include induction chemotherapy followed by chemoradiation, or chemoradiation followed by adjuvant chemotherapy. Cisplatin-based regimens remain the backbone of systemic therapy at these stages. In Stage IVB, where the cancer has spread to distant organs, systemic chemotherapy is the primary treatment, often using a combination of cisplatin with gemcitabine or fluorouracil. If the disease responds well to chemotherapy, patients may receive radiation therapy or chemoradiation afterward to control the primary tumor and involved lymph nodes. Increasingly, immune checkpoint inhibitors such as toripalimab or tislelizumab are also being incorporated into first-line treatment for recurrent or metastatic disease, signaling a shift toward immunotherapy in advanced settings.

Nasopharyngeal Carcinoma Epidemiology

The nasopharyngeal carcinoma cancer epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented as total incident cases of nasopharyngeal carcinoma, gender-specific incident cases of nasopharyngeal carcinoma, age-specific incident cases of nasopharyngeal carcinoma, and total treated cases of nasopharyngeal carcinoma in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034.

• Nasopharyngeal carcinoma are rare in the US with an incidence of 0.2–0.5 per 100,000 and peaking in those of the fourth to sixth decades.
• In 2020, there were 133,354 new nasopharyngeal carcinoma cases and 80,008 deaths were reported worldwide.
• Recurrence and/or metastasis (R/M) leads to treatment failure in about 20–30% of patients with advanced nasopharyngeal carcinoma.
• The rate of incidence of nasopharyngeal carcinoma increases from ages 20 to around 50. Also it occurs more often in men, with the incidence being 2.5 times higher in men than in women.

Nasopharyngeal Carcinoma Drug Chapters

The drug chapter segment of the nasopharyngeal carcinoma report encloses a detailed analysis of nasopharyngeal carcinoma marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also deep dives into nasopharyngeal carcinoma’s pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations.

Marketed Drugs

LOQTORZI (toripalimab-tpzi): Coherus/Junshi Biosciences

LOQTORZI binds to a protein called PD-1, which is found in T cells (a type of immune cell). Blocking this protein may help the immune system kill cancer cells. LOQTORZI is a type of monoclonal antibody and a type of immune checkpoint inhibitor. It is a prescription medicine developed to treat nasopharyngeal carcinoma by working with your immune system. It is incorporated intravenously. It is indicated in combination with cisplatin and gemcitabine, for first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma or as a single agent for the treatment of adults with recurrent unresectable or metastatic nasopharyngeal carcinoma with disease progression on or after a platinum-containing chemotherapy.

In October 2023, the US Food and Drug Administration (FDA) approved LOQTORZI (toripalimab), developed by Coherus BioSciences and Junshi Biosciences, for the treatment of recurrent or metastatic nasopharyngeal carcinoma across all lines of therapy. This marks the first FDA-approved treatment specifically for this rare cancer. The approval was based on the pivotal Phase III JUPITER-02 trial, which demonstrated significant clinical benefit when toripalimab was combined with chemotherapy in the first-line setting.

ANNIKO (penpulimab): Akeso Biopharma

ANNIKO works by stimulating your immune system by binding to the ""programmed death receptor"" (PD1) found on T-cells to help the immune system find and kill cancer cells. T-cells are a type of white blood cell that are important to how your immune system works.

ANNIKO has been approved in China for two indications: first-line treatment of advanced nasopharyngeal carcinoma and second or later line treatment of advanced nasopharyngeal carcinoma. In April 2025, the US FDA approved ANNIKO (Akeso Biopharma) with cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma.

Emerging Drugs

IAE0972: SunHo Biopharmaceutical

IAE0972, the EGFR-IL10 immunocytokine, was designed to aid in immune cell exhaustion in current immunotherapy, as well as to lift the limitations of current EGFR-based monoclonal antibodies. In IAE0972, IL10 is a potent activator of antigen-specific CD8-positive T cells found within the tumor microenvironment. It is able to restore the tumor-killing activity of tumor-infiltrating lymphocytes by restoring the oxidative phosphorylation metabolism of terminally exhausted T cells.

IAE0972 combined with chemotherapy, is being evaluated in the Phase II/III for recurrent/metastatic HNSCC/ nasopharyngeal carcinoma after failure or progress of ≤2-line system therapy, and to determine the MTD of combined therapy.

GEN1160 (PRO1160): Gemnab

It is a topoisomerase I inhibitor that targets CD70, a protein expressed on both solid tumors and hematological malignancies including renal cell carcinoma, nasopharyngeal carcinoma, and non-Hodgkin lymphoma. The drug was a part of the pipeline of ProfoundBio. In April 2024, the company was acquired by Genmab.

Currently, GEN1160 (PRO1160) is being evaluated in Phase I/II for solid tumors including nasopharyngeal carcinoma.

Drug Class Insights

Currently the landscape of nasopharyngeal carcinoma had many PD-1/PD-L1 directed therapies. PD-1/PD-L1 provides a mechanism of immune escape, the blockade of which has already been accomplished in various cancers and has reinvigorated interest in the treatment of nasopharyngeal carcinoma. Currently, the market holds potential therapies including ANNIKO and LOQTORZI, and many more. The drugs in these classes have been observed to have a fine efficacy, encouraging the upcoming drugs to take similar approaches. A Phase I combination of KFA115 ± Pembrolizumab is getting evaluated for advanced cancers including nasopharyngeal carcinoma.

Nasopharyngeal Carcinoma Market Outlook

Local disease nasopharyngeal carcinoma, classified as early stage I disease, encompasses patients with a tumor limited to the nasopharynx, or adjacent oropharynx, nasal cavity, without parapharyngeal involvement, and no lymph node or distant metastasis. Treatment at this stage has had limited advances regarding management, as international consensus establishes treatment with radiation therapy alone, as they are radiosensitive, have a limited surgical approach, and RT achieves excellent local control. Precisely, Intensity Modulated RT (IMRT) is the mainstay treatment at this stage. The market outlook for nasopharyngeal carcinoma treatment is still growing, driven by advancements in targeted therapies and immunotherapies. LOQTORZI, a PD-1 inhibitor, has started the treatment options for nasopharyngeal carcinoma, receiving FDA approval in 2023. ANNIKO, another PD-1 inhibitor, has recently received approval by the US FDA.

Key players, such as Genmab, SunHo Biopharmaceutical, and Novartis, and others, are evaluating their lead candidates in different stages of clinical development. They aim to investigate their products for the treatment of nasopharyngeal carcinoma.

Nasopharyngeal Carcinoma drug uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2025–2034, which depends on the competitive landscape, safety, and efficacy data along with order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

Further detailed analysis of emerging therapies drug uptake in the report…

Nasopharyngeal Carcinoma Activities

The report provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for nasopharyngeal carcinoma therapies.

KOL Views

To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including Medical/scientific writers, Professors, and Others.

DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as UT Health San Antonio MD Anderson Cancer Center, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or nasopharyngeal carcinoma market trends.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial’s primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival.

Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug. In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs including Medicare, Medicaid, Health Insurance Program (CHIP), and the state and federal health insurance marketplaces are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), and third-party organizations that provide services, and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of nasopharyngeal carcinoma, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Even though management of patients happens by off-label therapies, novel drug development is an ongoing opportunity for patients of this disease group. Market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach are included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM nasopharyngeal carcinoma market.

Nasopharyngeal Carcinoma Report Insights

• Patient Population
• Therapeutic Approaches
• Nasopharyngeal Carcinoma Pipeline Analysis
• Nasopharyngeal Carcinoma Market Size and Trends
• Existing and future Market Opportunity

Nasopharyngeal Carcinoma Report Key Strengths

• Ten Years Forecast
• 7MM Coverage
• Nasopharyngeal Carcinoma Epidemiology Segmentation
• Key Cross Competition
• Conjoint analysis
• Drugs Uptake and Key Market Forecast Assumptions

Nasopharyngeal Carcinoma Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs

• What is the historical and forecasted nasopharyngeal carcinoma patient pool/patient burden in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Which combination treatment approaches will have a significant impact on the nasopharyngeal carcinoma drug treatment market size?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
• What are the current and emerging options for the treatment of nasopharyngeal carcinoma?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies?
• How many key players are developing therapies for nasopharyngeal carcinoma?
• Which drug will be the major contributor nasopharyngeal carcinoma market by 2034?

Reasons to buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the nasopharyngeal carcinoma market.
• Insights on patient burden/disease Incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Please Note: It will take 7-10 business days to complete the report upon order confirmation. Show more